Low-Dose Acetylsalicylic Acid in Treating Patients With Stage I-III Non-Small Cell Lung Cancer
Stopped early · Early Phase 1
Conditions studied: Adenocarcinoma of the Lung, Recurrent Non-small Cell Lung Cancer, Stage IA Non-small Cell Lung Cancer, Stage IB Non-small Cell Lung Cancer, Stage IIA Non-small Cell Lung Cancer, Stage IIB Non-small Cell Lung Cancer, Stage IIIA Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer
In brief
This pilot clinical trial studies low-dose acetylsalicylic acid in treating patients with stage I-III non-small cell lung cancer. Studying samples of urine and blood from patients with cancer in the laboratory may help doctors learn more about changes in biomarkers that occur during treatment with acetylsalicylic acid
Key facts
- Study ID
- NCT01707823
- Run by
- Vanderbilt-Ingram Cancer Center
- People needed
- 4
- Starts
- 2012-10-01
- Expected to finish
- 2018-08-01
- Last updated by the study team
- 2020-01-14
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Have confirmed (stage IIIb-IV) or recurrent non-small cell lung cancer, adenocarcinoma histology
- Understand and voluntarily sign an informed consent document prior to any study related assessments or procedures are conducted
- Anticipated that they will complete all study procedures
- Ability to swallow pills
- No aspirin in the last 7 days
You may not qualify if…
- Know allergy to aspirin or other nonsteroidal anti-inflammatory drugs
- History of allergic reaction to aspirin or other non-steroidal anti-inflammatory drugs, including ibuprofen
- Any other concomitant serious illness or organ system dysfunction which in the opinion of the investigator would either compromise patient safety
Where it is running
- Vanderbilt-Ingram Cancer Center — Nashville, Tennessee, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.